Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SYL-1801 by Sylentis SAU for Choroidal Neovascularization: Likelihood of Approval
SYL-1801 is under clinical development by Sylentis SAU and currently in Phase II for Choroidal Neovascularization. According to GlobalData, Phase...
Data Insights
SYL-1801 by Sylentis SAU for Age Related Macular Degeneration: Likelihood of Approval
SYL-1801 is under clinical development by Sylentis SAU and currently in Phase II for Age Related Macular Degeneration. According to...